L. Lupinacci

发表

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

C. Wheeler, R. Railkar, K. Jansen, 2004, Vaccine.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.

P. Sax, K. Squires, P. Cahn, 2019, The lancet. HIV.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

S. Jagannath, J. Hardwick, G. Schiller, 2012, Clinical lymphoma, myeloma & leukemia.

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

C. Wheeler, R. Railkar, M. Lehtinen, 2006, Vaccine.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, C. Orkin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

P. Sax, K. Squires, P. Cahn, 2018, The lancet. HIV.

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Martin O. Leach, Nina Tunariu, Robert A. Beckman, 2014, Clinical Cancer Research.

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

David Olmos, A. Tolcher, K. Papadopoulos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.

A. Tolcher, K. Papadopoulos, A. Patnaik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.

A. Tolcher, A. Patnaik, M. Garrett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).

M. Dimopoulos, K. Anderson, S. Jagannath, 2010 .

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2009 .